With 25 years of expertise in cell therapy, immunology and virology across fundamental, translational and clinical stages, Etablissement Français du Sang (EFS) combines strong capabilities in translational research, GMP-grade bioproduction and access to high-quality biological samples.

EFS operates four ATMP bioproduction platforms across France as a CDMO, supporting clinical manufacturing for a broad range of cell types including MSC, CAR-T, iPSC, hESC and HSC. EFS also performs the GMP manufacturing of cell banks (Master & Working) for its partners.

In addition, EFS has strenghten its offer, through its PIBT (Pôle d’Innovation en Biothérapies), a dedicated development platform, focused on the maturation of advanced therapy projects. This includes the evaluation and integration of innovative bioproduction technologies, process and analytical development, and scalability, with early consideration of manufacturing and GMP constraints.

Together, these capabilities provide a continuum from early-stage development to clinical production, enabling a smoother and more reliable transition toward industrialisation.

Inpart, the platform purpose-built for biopharma partnering and external innovation.

Trusted by 500+ organizations across the life sciences ecosystem, including 70% of the world’s top 50 pharmaceutical companies. Inpart helps life science teams discover and evaluate external innovation more effectively.

Through a global scientific discovery network spanning 3,000+ research institutions and 6,000+ emerging biotech companies, they proactively surface new partnering opportunities aligned with our clients’ scientific priorities.

Inpart’s AI-enabled platform then supports the full partnering lifecycle; helping BD, R&D, Alliance Management and leadership teams structure evaluation workflows, collaborate across teams, and capture critical decision insights. By transforming fragmented evaluation data into structured intelligence, organizations gain better visibility across their external pipeline and unlock the foundation for AI-driven insight.

Deal is Inpart’s industry-leading partnering intelligence platform that helps BD, R&D, Alliance Management and leadership teams structure the evaluation and management of external opportunities across the partnering life-cycle. The platform captures scientific and commercial evaluation data, enables efficient collaboration across teams, and creates a clear history of partnering evaluations and decisions.

By transforming fragmented opportunity data into structured intelligence, Deal unlocks AI-driven insights that help organizations surface patterns across evaluations, identify strategic gaps, and generate portfolio-level visibility, enabling leadership teams to answer critical partnering questions in minutes and make faster, more reliable decisions.

Inscoper provides high-performance super-resolution imaging solutions for Biopharma and CRO applications through its liveDRIM™ system. Optimized for organoids, 3D cell models, and high-content workflows, it delivers 100 nm resolution in thick, live samples without the typical trade-offs between speed, depth, and cell viability.

Inscoper also facilitates advanced microscopy workflows and custom OEM configurations. It helps generate the robust metrics needed for protocol development, and delivers the reproducible, analysis-ready data required to validate complex therapeutic approaches in diverse R&D environments.